15502 Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 

Executive Blvd., Bethesda, MD 20892. (301) 

496–8683. singhs@nidcd.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7718 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Training in Clinical 

Radiation Therapy Physics and Dosimetry. 

Date: April 24, 2009. 

Time: 2 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 , 

(Telephone Conference Call). 

Contact Person: Katrin Eichelberg, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892, 301–496– 

0818, keichelberg@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Clinical and Pediatric Loan 

Repayment Programs. 

Date: April 30–May 1, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Erica L. Brown, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301– 

451–2639, ebrown@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Clinical and Pediatric Loan 

Repayment Program. 

Date: May 7–8, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Erica L. Brown, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301– 

451–2639, ebrown@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7721 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel; Special Emphasis Panel 

Review of R25 Applications. 

Date: May 20, 2009. 

Time: 1 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Mary Kelly, Scientific 

Review Officer, Scientific Review Branch, 

National Institute of Dental & Craniofacial 

Research, NIH 6701 Democracy Blvd., Room 

672, MSC 4878, Bethesda, MD 20892–4878, 

301–594–4809, mary_kelly@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7723 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 15503 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227. 414–328– 

7840/800–877–7016. (Formerly: 

Bayshore Clinical Laboratory.) 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624. 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118. 901–794–5770/888–290– 

1150. 

Aegis Sciences Corporation, 345 Hill 

Ave., Nashville, TN 37210. 615–255– 

2400. (Formerly: Aegis Analytical 

Laboratories, Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299. 501–202–2783. 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center.) 

Clendo Reference Laboratory, Avenue, 

Santa Cruz #58, Bayamon, Puerto Rico 

00959. 787–620–9095. 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802. 800– 

445–6917. 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913. 239–561–8200/800–735– 

5416. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602. 229–671– 

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974. 

215–674–9310. 

DynaLIFE Dx *, 10150–102 St., Suite 

200, Edmonton, Alberta, Canada T5J 

5E2. 780–451–3702/800–661–9876. 

(Formerly: Dynacare Kasper Medical 

Laboratories.) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655. 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories *, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4. 519– 

679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053. 504– 

361–8989/800–433–3823. (Formerly: 

Laboratory Specialists, Inc.) 

Kroll Laboratory Specialists, Inc., 450 

Southlake Blvd., Richmond, VA 

23236. 804–378–9130. (Formerly: 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040. 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869. 908–526–2400/800–437–4986. 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709. 

919–572–6900/800–833–3984. 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group.) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671. 866–827–8042/ 

800–233–6339. (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center.) 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219. 913–888–3927/800–873–8845. 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Maxxam Analytics *, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8. 905–817–5700. (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112. 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE. 2nd Ave., Portland, OR 

97232. 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417. 612–725– 

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304. 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504. 888–747–3774. (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory.) 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311. 

800–328–6942. (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory.) 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204. 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121. 858–643– 

5555. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340. 

770–452–1590/800–729–6432. 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories.) 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403. 

610–631–4600/877–642–2216. 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories.) 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405. 

866–370–6699/818–989–2521. 

(Formerly: SmithKline Beecham 

Clinical Laboratories.) 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109. 505– 

727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601. 574–234–4176 x276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040. 602–438–8507/800–279– 

0027. 

Sparrow Health System, Toxicology 

Testing Center, St. Lawrence Campus, 

1210 W. Saginaw, Lansing, MI 48915. 

517–364–7400. (Formerly: St. 

Lawrence Hospital & Healthcare 

System.) 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101. 405–272– 

7052. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 


pwalker on PROD1PC71 with NOTICES
15504 Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 

70 West, Suite 208, Columbia, MO 

65203. 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

NW. 79th Ave., Miami, FL 33166. 

305–593–2260. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235. 301–677–7085. 

*The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 13, 2004 (69 FR 

19644). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Elaine Parry, 

Director, Office of Program Services, 

SAMHSA. 

[FR Doc. E9–7379 Filed 4–3–09; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2009–0076] 

Navigation Safety Advisory Council; 

Meeting 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of meeting. 

SUMMARY: The Navigation Safety 

Advisory Council (NAVSAC) will meet 

in May 2009 in Savannah, GA, to 

discuss various issues relating to the 

safety of navigation. The meeting will be 

open to the public. 

DATES: NAVSAC will meet on 

Wednesday, May 20, 2009, from 8 a.m. 

to 5 p.m., and Thursday, May 21, 2009, 

from 8 a.m. to 5 p.m. The meeting may 

close early if all business is finished. 

Written material and requests to make 

oral presentations should reach the 

Coast Guard on or before May 5, 2009. 

Requests to have a copy of your material 

distributed to each member of the 

committee should reach the Coast Guard 

on or before May 5, 2009. 

ADDRESSES: NAVSAC will meet at the 

Hyatt Regency Savannah, Two West Bay 

Street, Savannah, GA 31401. Send 

written material and requests to make 

oral presentations to Mr. John Bobb, the 

Assistant Designated Federal Officer 

(ADFO), Commandant (CG–54121), U.S. 

Coast Guard Headquarters, 2100 Second 

Street, SW., Washington, DC 20593– 

0001. This notice may be viewed in our 

online docket, USCG–2009–0076, at 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Mike Sollosi, the Designated Federal 

Officer (DFO) of NAVSAC, telephone 

202–372–1545, or e-mail at 

mike.m.sollosi@uscg.mil, or Mr. John 

Bobb, the ADFO, telephone 202–372– 

1532, fax 202–372–1929, or e-mail at 

john.k.bobb@uscg.mil. 

SUPPLEMENTARY INFORMATION: Notice of 

the meeting is given under the Federal 

Advisory Committee Act, 5 U.S.C. App. 

(Pub. L. 92–493). 

Agenda of Meeting 

The agenda for the May 20–21, 2009, 

NAVSAC meeting is as follows: 

(1) Offshore Renewable Energy 

Installations (OREI) NVIC 02–07 

Review. 

(2) Unmanned Autonomous Vessels 

COLREGS Applicability. 

(3) Barge Lighting Study. 

(4) eNav User Needs Study. 

(5) Vessel Traffic System. 

Procedural 

The meeting is open to the public. 

Please note that the meeting may close 

early if all business is finished. At the 

Chair’s discretion, members of the 

public may make oral presentations 

during the meeting. If you would like to 

make an oral presentation at the 

meeting, please notify the DFO or ADFO 

no later than May 5, 2009. Written 

material for distribution at the meeting 

should reach the Coast Guard no later 

than May 5, 2009. If you would like a 

copy of your material distributed to 

each member of the committee in 

advance of the meeting, please submit 

20 copies to the DFO or ADFO no later 

than May 5, 2009. 

Information on Services for Individuals 

With Disabilities 

For information on facilities or 

services for individuals with disabilities 

or to request special assistance at the 

meeting, contact the DFO or ADFO as 

soon as possible. 

Dated: March 9, 2009. 

Wayne A. Muilenburg, 

Captain, U.S. Coast Guard, Office of 

Waterways Management. 

[FR Doc. E9–7667 Filed 4–3–09; 8:45 am] 

BILLING CODE 4910–15–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Accreditation and Approval of Amspec 

Services LLC, as a Commercial Gauger 

and Laboratory 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of accreditation and 

approval of Amspec Services LLC, as a 

commercial gauger and laboratory. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.12 and 19 CFR 

151.13, Amspec Services LLC, 12154 B 

River Road, St. Rose, LA 70087, has 

been approved to gauge and accredited 

to test petroleum and petroleum 

products, organic chemicals and 

vegetable oils for customs purposes, in 

accordance with the provisions of 19 

CFR 151.12 and 19 CFR 151.13. Anyone 

wishing to employ this entity to conduct 

laboratory analyses and gauger services 

should request and receive written 

assurances from the entity that it is 

accredited or approved by the U.S. 

Customs and Border Protection to 

conduct the specific test or gauger 

service requested. Alternatively, 

inquiries regarding the specific test or 

gauger service this entity is accredited 

or approved to perform may be directed 

to the U.S. Customs and Border 

Protection by calling (202) 344–1060. 

The inquiry may also be sent to 

cbp.labhq@dhs.gov. Please reference the 

Web site listed below for a complete 

listing of CBP approved gaugers and 

accredited laboratories: http://cbp.gov/

xp/cgov/import/operations_support/

labs_scientific_svcs/commercial_

gaugers/. 

DATES: The accreditation and approval 

of Amspec Services LLC, as commercial 

gauger and laboratory became effective 

on December 4, 2008. The next triennial 


pwalker on PROD1PC71 with NOTICES